Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Roche”

Slow-SPEED: Slowing Parkinson's Early Through Exercise DosageNot Yet Recruiting
NCT06993142NAUpdated Jun 3, 2025
Sponsor: Radboud University Medical Center
Parkinson Disease · Prodromal Stage · Neurodegenerative Diseases · Basal Ganglia Diseases
United States, Netherlands
Characterization of Cerebral Tau Aggregates With 18F-RO6958948 PET in the ALFA PopulationEnrolling By Invitation
NCT04482660NAUpdated May 31, 2025
Sponsor: Barcelonabeta Brain Research Center, Pasqual Maragall Foundation
Healthy · Mild Cognitive Impairment
Spain
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid TumorsCompleted
NCT03037385Phase 1, Phase 2Updated May 31, 2025
Sponsor: Hoffmann-La Roche
RET-altered Non Small Cell Lung Cancer · Medullary Thyroid Cancer · RET-altered Papillary Thyroid Cancer · RET-altered Colon Cancer
United States, Belgium, China, France, Germany +8 more
Patient-Centric Study to Assess the Impact of Genomic Profiling on the Treatment of Patients With Metastatic Breast Cancer in SpainRecruiting
NCT06991946N/AUpdated May 28, 2025
Sponsor: SOLTI Breast Cancer Research Group
Metastatic Breast Cancer
Spain
A Study Evaluating the Safety, Pharmacokinetic and Anti-tumor Activity of RO7428731 in Participants With GlioblastomaCompleted
NCT05187624Phase 1Updated May 22, 2025
Sponsor: Hoffmann-La Roche
Glioblastoma
United States, Australia, Canada, Denmark, Spain
A Study to Evaluate the Safety and Tolerability of RO7296682 in Combination With Atezolizumab in Participants With Advanced Solid Tumors.Terminated
NCT04642365Phase 1Updated May 21, 2025
Sponsor: Hoffmann-La Roche
Solid Tumors
United States, Australia, Belgium, Canada, Denmark +1 more
Adult SMA Research and Clinical HubRecruiting
NCT06978985N/AUpdated May 18, 2025
Sponsor: Newcastle-upon-Tyne Hospitals NHS Trust
Spinal Muscular Atrophy (SMA)
United Kingdom
Check@Home: General Population Screening for Early Detection of Atrial Fibrillation and Chronic Kidney DiseaseEnrolling By Invitation
NCT06330480NAUpdated May 16, 2025
Sponsor: Prof. Dr. Folkert W. Asselbergs
Atrial Fibrillation · Chronic Kidney Diseases · Diabetes Mellitus, Type 2
Netherlands
A Trial of Ipatasertib in Combination With AtezolizumabActive Not Recruiting
NCT03673787Phase 1, Phase 2Updated May 14, 2025
Sponsor: Institute of Cancer Research, United Kingdom
Solid Tumor · Glioblastoma Multiforme · Prostate Cancer Metastatic
United Kingdom
Atezolizumab Trial in Endometrial Cancer - AtTEndCompleted
NCT03603184Phase 3Updated May 9, 2025
Sponsor: Mario Negri Institute for Pharmacological Research
Endometrial Cancer
Australia, Austria, Germany, Italy, Japan +6 more
Untreated FolliculaR Lymphoma Treated With OBinituzumAb in a Non-interventional Study (URBAN)Completed
NCT04034056N/AUpdated May 9, 2025
Sponsor: Hoffmann-La Roche
Follicular Lymphoma
Italy
A Study of Atezolizumab in Combination With Bevacizumab in Spanish Patients With Unresectable or Unsuitable for Locoregional Treatments Hepatocellular Carcinoma Not Previously Treated With Systemic TherapyTerminated
NCT04732286Phase 3Updated May 8, 2025
Sponsor: Hoffmann-La Roche
Carcinoma, Hepatocellular
Spain
Effect of Omalizumab in the Skin of Food Allergy PatientsRecruiting
NCT06618963Phase 4Updated May 2, 2025
Sponsor: National Jewish Health
Food Allergy · Food Allergy in Children
United States
Registry for Molecular Testing, Treatment and Outcome of Patients With Solid Tumors Harboring a NTRK Gene FusionCompleted
NCT04557813N/AUpdated May 1, 2025
Sponsor: iOMEDICO AG
NTRK Family Gene Mutation
Germany, Switzerland
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered Mosunetuzumab to Participants With Systemic Lupus ErythematosusCompleted
NCT05155345Phase 1Updated Apr 29, 2025
Sponsor: Hoffmann-La Roche
Systemic Lupus Erythematosus
United States, Moldova, Poland
SOFIA-LTT Study: A Study of Intermittent Long Term Treatment With PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg Negative Chronic Hepatitis B (CHB).Completed
NCT00442572Phase 2Updated Apr 24, 2025
Sponsor: Hoffmann-La Roche
Hepatitis B, Chronic
Bulgaria
Study of Atezolizumab Combined With Split-dose Gemcitabine Plus Cisplatin in Urothelial CarcinomaCompleted
NCT04602078Phase 2Updated Apr 24, 2025
Sponsor: Spanish Oncology Genito-Urinary Group
Locally Advanced or Metastatic Urothelial Carcinoma
Spain
A Trial Looking at Rituximab and Chemotherapy as a Treatment for Follicular Lymphoma in Elderly PatientsCompleted
NCT01303887Phase 3Updated Apr 18, 2025
Sponsor: University of Liverpool
Follicular Lymphoma
United Kingdom
Genomic Testing and Resulting Medical DecisionsCompleted
NCT03301493N/AUpdated Apr 10, 2025
Sponsor: Arbeitsgemeinschaft medikamentoese Tumortherapie
Cancer of Unknown Origin · Cancer Refractory · Cancer of Stomach · Cancer Head Neck
Austria
Metastatic Breast Cancer in AustriaRecruiting
NCT03870620N/AUpdated Apr 10, 2025
Sponsor: Arbeitsgemeinschaft medikamentoese Tumortherapie
Breast Cancer · Breast Carcinoma · Breast Tumor
Austria
AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic StrokeTerminated
NCT03192215Phase 3Updated Apr 9, 2025
Sponsor: Columbia University
Stroke
United States, Canada
Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian CancerCompleted
NCT03353831Phase 3Updated Apr 6, 2025
Sponsor: AGO Research GmbH
Recurrent Ovarian Carcinoma
Austria, Belgium, Denmark, Estonia, Finland +7 more
The Clinical Impact of Cobas® Eplex Blood Culture Panels for the Diagnosis of Bacteremia and FungemiaRecruiting
NCT06576258NAUpdated Apr 2, 2025
Sponsor: University Hospital, Antwerp
Bloodstream Infection
Belgium
HER2 Imaging Study to Identify HER2 Positive Metastatic Breast Cancer Patient Unlikely to Benefit From T-DM1Completed
NCT01565200Phase 2Updated Mar 31, 2025
Sponsor: Jules Bordet Institute
HER-2 Positive Breast Cancer
Belgium, Netherlands
Frontline Treatment of Follicular Lymphoma With AtezolizUmab and Obinutuzumab With and Without RadiOtherapyActive Not Recruiting
NCT04962126Phase 2Updated Mar 21, 2025
Sponsor: Olivia Newton-John Cancer Research Institute
Follicular Lymphoma
Australia

Previous page Next page